23.5 C
Australia
Sunday, October 25, 2020

COVID Vaccine Covishield trials conduct by SII in India

Must read

Sheffield Protect: Moises Henriques rescued NSW with

Australia’s Check all-rounder-in-waiting is near resuming bowling within the Sheffield Protect.WA’s rising star Cameron Inexperienced is being managed after injuring his again final...

Tinder: On-line courting app Tinder updates security options after assault claims

Tinder has up to date its security options after allegations sexual predators and abusers are exploiting the courting app to search out victims,...
The Indian Telegraphhttps://theindiantelegraph.com.au/
Established in 2007, The Indian Telegraph is a multi award winning digital media company based in Australia.

The Serum Institute of India (SII) will launch the first Covid-19 vaccine called ‘Covishield’ and commence its trials soon in India.

SII released a representative image of the vial of Covishield which is the vaccine developed by the Oxford University and pharma giant, AstraZeneca.

Adar Poonawalla, CEO, SII, in a tweet, said: “Congratulations to the teams at @UniofOxford and @AstraZeneca for getting this product data out. It all seems to be going well. Hope to get positive results in the phase three trials in a few months. We have also hope to start phase three trials in India soon”.

The SII will be applying soon for the licensure trials of AstraZeneca Oxford vaccine to the Indian regulator.

Commenting on the AstraZeneca-Oxford Vvaccine’s results, Poonawalla said: “The trials have shown promising results and we are extremely happy about it. We will be applying for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with the trials for the vaccine in India. In addition, we will soon start manufacturing the vaccine in large volumes.”

Monday marked an important day in the battle against Covid as the first results of Oxford’s Covid-19 vaccine show it is safe and provokes an immune reaction in a person that lasts for almost two months.

The researchers are indicating that the vaccine may be ready by year-end. The results showed that more than 91 per cent of volunteers injected produced an immune response against the coronavirus that lasted a month or more. The immune responses remained strong for at least 56 days.

Oxford University’s vaccine – called AZD1222 – is being manufactured by pharmaceutical major AstraZeneca and the UK Government has ordered 100 million doses ahead of time.

As per the results, the vaccine boosted T cell and antibody immunity. The vaccine produced a strong responses on both accounts, the study found, with T cell immunity peaking after two weeks and then dropping slightly by day 56.

Antibody immunity, on the other hand, peaked after four weeks and remained high by day 56, indicating that it may well last for even longer.

Latest article

Scam 1992 Review Watch Online

Hansal Mehta's Scam 1992 is the story of the rise and fall of the Big Bull Of Dalal Street, Harshad Mehta.

Harshad Mehta Scam 1992

Who is Harshad Mehta? Harshad Mehta was a well known Indian stockbroker, who was known for his wealth and was charged...

Melbourne COVID-19 restrictions: Companies slam Dan Andrews’ delay

Companies have slammed Daniel Andrews’ “cautious pause” on easing restrictions, after a hoped-for announcement that retail and hospitality may start opening was delayed...

Coronavirus Victoria: Scott Morrison criticises Dan Andrews’ continued lockdown

Prime Minister Scott Morrison has lashed out at Victorian Premier Daniel Andrews over his decision not to lift coronavirus restrictions, keeping the vast...

Weather forecast Australia: Severe storms likely to strike the east coast

Hail almost as large as tennis balls could strike across eastern Australia next week as severe thunderstorms are predicted. The east coast is...